# Axela

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/axela

- Industry: Healthcare
- Headquarters: Toronto, Canada
- Website: www.axelabiosensors.com
- Total disclosed funding: $3.7M
- Latest round: Series A (May 6, 2005)
- Investors on record: 3

## About

Axela Inc. is a Canadian biosensor technology company that develops innovative diagnostic solutions for healthcare, enhancing disease detection and monitoring capabilities.Founded in 2005 and headquartered in Toronto, Canada, Axela Inc. specializes in advanced biosensor technology. The company was led by founder Sebastian Huisman, who has a history of entrepreneurial ventures. In February 2012, Axela raised CAD 2.13 mn in a funding round led by VenGrowth Capital Partners, which represents the total amount raised since inception. The company has completed a total of five deals, with the most recent deal occurring on 28 February 2012.Axela Biosensors specializes in advanced biosensor technology, focusing on innovative diagnostic solutions that cater to various healthcare needs. The company's flagship products include a range of biosensors designed to perform real-time, on-site analysis of biological samples, allowing for rapid diagnostics in clinical settings. These products are primarily aimed at healthcare providers, laboratories, and research institutions, addressing critical challenges in disease detection and monitoring. With applications spanning infectious diseases, chronic conditions, and personalized medicine, Axela's offerings streamline workflows and enhance patient outcomes. Geographically, the company targets markets in North America, Europe, and Asia, ensuring a broad reach among diverse healthcare systems.Axela Biosensors generates revenue through direct sales of its biosensor products to healthcare institutions and research facilities, employing a B2B transaction model. The company engages in strategic partnerships with key healthcare providers to facilitate bulk purchases and long-term agreements. Revenue is driven by the sale of individual biosensor units as well as potential subscription models for ongoing support and maintenance services. Specific pricing structures for flagship products are established to reflect their innovative technology and value proposition within the diagnostics market, ensuring competitive positioning. Given the critical nature of their products, clients often prioritize reliability and accuracy, further driving demand for Axela's offerings.Axela Inc. is focused on expanding its product lineup with upcoming biosensor technologies aimed at improving diagnostic capabilities. The company is strategizing to enter new markets in Asia and Europe by 2015, leveraging recent funding of CAD 2.13 mn raised in February 2012 to support these initiatives. This investment will be pivotal in enhancing research and development efforts to accelerate product launch timelines and bolster marketing strategies in targeted expansion regions.

## Funding rounds

- Series A, May 6, 2005, $3.7M — VenGrowth Capital Partners, Primaxis Technology Ventures, Royal Bay Capital

## Investors

- VenGrowth Capital Partners (https://capitalatlas.ai/funds/vengrowth-capital-partners) — Series A
- Primaxis Technology Ventures (https://capitalatlas.ai/funds/primaxis-technology-ventures) — Series A
- Royal Bay Capital (https://capitalatlas.ai/funds/royal-bay-capital) — Series A